{"id":"https://openalex.org/W4379980239","doi":"https://doi.org/10.1002/hon.3165_603","title":"UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) POST\u2010BRUTON TYROSINE KINASE INHIBITOR (BTKI): A SYSTEMATIC LITERATURE REVIEW AND META\u2010ANALYSIS","display_name":"UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) POST\u2010BRUTON TYROSINE KINASE INHIBITOR (BTKI): A SYSTEMATIC LITERATURE REVIEW AND META\u2010ANALYSIS","alternate_titles":[],"publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379980239","doi":"https://doi.org/10.1002/hon.3165_603"},"language":"en","primary_location":{"id":"doi:10.1002/hon.3165_603","doi":"https://doi.org/10.1002/hon.3165_603","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3165_603","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_603","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4379980239"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_603","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046049357","display_name":"Martin H. Dreyling","orcid":"https://orcid.org/0000-0002-0358-5249","observed_orcids":["https://orcid.org/0000-0002-0358-5249"]},"institutions":[{"id":"https://openalex.org/I3018771216","display_name":"LMU Klinikum","ror":"https://ror.org/02jet3w32","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]},{"id":"https://openalex.org/I8204097","display_name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","ror":"https://ror.org/05591te55","country_code":"DE","type":"education","lineage":["https://openalex.org/I8204097"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Dreyling","raw_affiliation_strings":["LMU Hospital, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LMU Hospital, Munich, Germany","institution_ids":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025137989","display_name":"Bijal Dinesh Shah","orcid":"https://orcid.org/0000-0003-4328-6021","observed_orcids":["https://orcid.org/0000-0003-4328-6021"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B. Shah","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113904171","display_name":"James J. Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142892","display_name":"Kite (United States)","ror":"https://ror.org/04tnhnq23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142892"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Wu","raw_affiliation_strings":["Kite, a Gilead Company, Santa Monica, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, a Gilead Company, Santa Monica, USA","institution_ids":["https://openalex.org/I4210142892"]}]},{"author_position":"middle","author":{"id":null,"display_name":"T. Itani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210156700","display_name":"Gilead Sciences (Germany)","ror":"https://ror.org/05dh8ar36","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210140816","https://openalex.org/I4210156700"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Itani","raw_affiliation_strings":["Kite, a Gilead Company, Munich, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, a Gilead Company, Munich, Germany","institution_ids":["https://openalex.org/I4210156700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005850256","display_name":"Michael J. Zoratti","orcid":"https://orcid.org/0000-0003-3069-1159","observed_orcids":["https://orcid.org/0000-0003-3069-1159"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. J. Zoratti","raw_affiliation_strings":["RainCity Analytics, Vancouver, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RainCity Analytics, Vancouver, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056574916","display_name":"Steve Kanters","orcid":"https://orcid.org/0000-0003-0322-5398","observed_orcids":["https://orcid.org/0000-0003-0322-5398"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. Kanters","raw_affiliation_strings":["RainCity Analytics, Vancouver, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RainCity Analytics, Vancouver, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034329124","display_name":"Sally West Wade","orcid":"https://orcid.org/0000-0003-4726-7995","observed_orcids":["https://orcid.org/0000-0003-4726-7995"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"S. W. Wade","raw_affiliation_strings":["Wade Outcomes Research & Consulting Salt Lake City USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wade Outcomes Research & Consulting Salt Lake City USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113278909","display_name":"W. Peng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142892","display_name":"Kite (United States)","ror":"https://ror.org/04tnhnq23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142892"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"W. Peng","raw_affiliation_strings":["Kite, a Gilead Company, Santa Monica, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, a Gilead Company, Santa Monica, USA","institution_ids":["https://openalex.org/I4210142892"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110035836","display_name":"Jean\u2010Gabriel Castaigne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162951","display_name":"Gilead Sciences (France)","ror":"https://ror.org/05d14ax96","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210140816","https://openalex.org/I4210162951"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Castaigne","raw_affiliation_strings":["Kite, a Gilead Company, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, a Gilead Company, Paris, France","institution_ids":["https://openalex.org/I4210162951"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023792802","display_name":"Ioana Kloos","orcid":"https://orcid.org/0009-0004-3243-8450","observed_orcids":["https://orcid.org/0009-0004-3243-8450"]},"institutions":[{"id":"https://openalex.org/I4210162951","display_name":"Gilead Sciences (France)","ror":"https://ror.org/05d14ax96","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210140816","https://openalex.org/I4210162951"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"I. Kloos","raw_affiliation_strings":["Kite, a Gilead Company, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, a Gilead Company, Paris, France","institution_ids":["https://openalex.org/I4210162951"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Wang","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4220,"currency":"USD","value_usd":4220},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"S2","first_page":"755","last_page":"757"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.953000009059906},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9509999752044678},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.6880000233650208},{"id":"https://openalex.org/keywords/brexucabtagene-autoleucel","display_name":"brexucabtagene autoleucel","score":0.9369999766349792},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8870000243186951},{"id":"https://openalex.org/keywords/unmet-medical-need","display_name":"unmet clinical needs","score":0.7260000109672546},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9200000166893005},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":1.0},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9629999995231628},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7590000033378601},{"id":"https://openalex.org/keywords/b-cell-non-hodgkin-lymphoma","display_name":"B-cell non-Hodgkin lymphoma","score":0.8029999732971191},{"id":"https://openalex.org/keywords/individual-patient-data","display_name":"individual patient data","score":0.4970000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7217439413070679},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.6273021697998047},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5501759648323059},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.4282175302505493},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37657231092453003},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/hon.3165_603","doi":"https://doi.org/10.1002/hon.3165_603","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3165_603","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_603","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1002/hon.3165_603","doi":"https://doi.org/10.1002/hon.3165_603","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1002/hon.3165_603","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3165_603","source":{"id":"https://openalex.org/S23714410","display_name":"Hematological Oncology","issn_l":"0278-0232","issn":["0278-0232","1099-1069"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematological Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"},{"display_name":"Meta-Analysis","id":"https://openalex.org/study-designs/meta-analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320314458","display_name":"National Comprehensive Cancer Network","ror":"https://ror.org/0465x5x63"},{"id":"https://openalex.org/F4320327235","display_name":"Servier","ror":"https://ror.org/034e7c066"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4379980239.pdf","grobid_xml":"https://content.openalex.org/works/W4379980239.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4386282283","https://openalex.org/W4400416528","https://openalex.org/W4214532611","https://openalex.org/W4283517144","https://openalex.org/W2986117184","https://openalex.org/W4388424459","https://openalex.org/W4386271131","https://openalex.org/W2950197990","https://openalex.org/W7166121090","https://openalex.org/W4417017097"],"abstract_inverted_index":{"Background:":[0],"Most":[1],"patients":[2,27,56,94,151,169,178,207,218,256,274,289],"with":[3,57,75,117,153,184,199,224,304,308,352],"MCL,":[4],"a":[5,141,185,209,276,337,357,375,472,491,550,563,576],"rare":[6],"B-cell":[7,380],"non-Hodgkin":[8,381],"lymphoma,":[9,382],"will":[10],"relapse":[11],"or":[12,32,98,189,323,395,431,468,487,533,546,559,572,586],"become":[13],"refractory":[14],"to":[15,30,47,72,173,231,319,389],"treatment.":[16],"While":[17],"the":[18,51,61,103,134,165,214,225,331,390],"introduction":[19],"of":[20,55,78,93,110,167,206,211,273,288,311,386],"BTKis":[21,37],"has":[22,505,520],"been":[23],"transformative,":[24],"options":[25,329],"for":[26,150,182,190,247,254,348,512,527],"who":[28,290],"fail":[29],"respond":[31],"whose":[33],"disease":[34],"progresses":[35],"on":[36,115,133,299],"remain":[38],"limited":[39],"and":[40,49,67,155,222,235,243,259,271,282,295,301,313,336],"largely":[41],"palliative":[42],"in":[43,60,102,241,330,360],"nature.":[44],"We":[45],"sought":[46],"characterize":[48],"quantify":[50],"unmet":[52,339],"clinical":[53,340],"need":[54,341],"R/R":[58],"MCL":[59],"post-BTKi":[62,104,192,332],"setting.":[63,105,363],"Methods:":[64],"MEDLINE,":[65],"Embase,":[66],"CENTRAL":[68],"were":[69,112,138,147,175,179,219,239,280,316],"systematically":[70],"searched":[71],"October":[73],"2022\u2014supplemented":[74],"hand":[76],"searches":[77],"select":[79],"conferences\u2014to":[80],"identify":[81],"studies":[82,116,159,201,303],"reporting":[83,164,202],"overall":[84],"survival":[85,88,321,349],"(OS),":[86],"progression-free":[87],"(PFS),":[89],"and/or":[90],"response":[91,136,268,278],"outcomes":[92,166,203],"receiving":[95,208],"non-CAR-T":[96,154,196,248],"treatments":[97],"brexucabtagene":[99],"autoleucel":[100],"(brexu-cel)":[101],"Random":[106],"effects":[107,325],"bivariate":[108],"meta-analyses":[109],"OS/PFS":[111,253,287],"conducted":[113],"based":[114,132,298],"published":[118,240],"Kaplan-Meier":[119],"(KM)":[120],"curves":[121,238],"from":[122,171,204,229,508,523],"which":[123],"individual":[124],"patient":[125],"data":[126],"could":[127],"be":[128],"estimated.":[129],"Response":[130],"outcomes,":[131,350],"best":[135],"achieved,":[137],"meta-analyzed":[139],"using":[140],"generalized":[142],"linear":[143],"mixed":[144],"model.":[145],"Outcomes":[146],"evaluated":[148],"separately":[149],"treated":[152,170],"brexu-cel.":[156],"Results:":[157],"Twenty-six":[158],"(23":[160],"observational;":[161],"3":[162,244],"trials),":[163],"1845":[168],"2005":[172],"2022,":[174],"included,":[176],"where":[177],"initially":[180],"enrolled":[181],"treatment":[183,191,351],"BTKi":[186],"(12":[187],"studies)":[188],"(14":[193],"studies).":[194],"The":[195,250,265,285,364],"interventions":[197],"varied,":[198],"most":[200,217],"cohorts":[205],"variety":[210],"interventions.":[212],"Across":[213],"included":[215],"studies,":[216,245],"male":[220],"(65-94%)":[221],"older,":[223],"median":[226,252,286],"age":[227],"varying":[228],"63":[230],"77":[232],"years.":[233],"OS":[234],"PFS":[236],"KM":[237,305],"10":[242],"respectively,":[246,307],"outcomes.":[249],"pooled":[251,266],"these":[255],"was":[257,293,366,371],"9.1":[258],"7.6":[260],"months,":[261,297],"respectively":[262],"(Table":[263],"1).":[264],"objective":[267],"rate":[269],"(ORR)":[270],"percentage":[272],"achieving":[275],"complete":[277],"(CR)":[279],"45%":[281],"23%,":[283],"respectively.":[284],"received":[291,506,521],"brexu-cel":[292,353],"32.1":[294],"14.9":[296],"5":[300],"6":[302],"curves,":[306],"ORR/CR":[309],"rates":[310],"89%":[312],"74%.":[314],"Analyses":[315],"not":[317],"sensitive":[318],"different":[320],"distributions":[322],"fixed/random":[324],"models.":[326],"Conclusions:":[327],"Treatment":[328],"setting":[333],"are":[334],"heterogeneous":[335],"significant":[338],"persists.":[342],"Though":[343],"longer":[344],"follow-up":[345],"is":[346,354],"needed":[347],"emerging":[355],"as":[356],"promising":[358],"option":[359],"this":[361],"difficult-to-treat":[362],"research":[365,513,528],"funded":[367,372],"by:":[368],"This":[369],"study":[370],"by":[373],"Kite,":[374,471,490,549,562,575],"Gilead":[376,473,492,496,551,555,564,568,577,581],"company.":[377],"Keywords:":[378],"Aggressive":[379],"Cellular":[383],"therapies":[384],"Conflicts":[385],"interests":[387],"pertinent":[388],"abstract":[391],"M.":[392,498,583],"Dreyling":[393],"Consultant":[394,430,532,585],"advisory":[396,432,534,587],"role":[397,433,535,588],"Astra":[398,421],"Zeneca,":[399,422],"Beigene,":[400],"BMS/Celgene,":[401,411],"Gilead/Kite,":[402,412,423],"Janssen,":[403,413,417,424],"Lilly/Loxo,":[404],"Novartis,":[405,426],"Roche":[406,414,418,427],"Research":[407,448,501,516,690],"funding:":[408,449,502,517,691],"Abbvie,":[409],"Bayer,":[410],"Educational":[415,454],"grants:":[416,455],"Other":[419,458],"remuneration:":[420,459],"Lilly,":[425],"B.":[428],"Shah":[429],"Pepromene":[434,625],"Bio;":[435,626],"Takeda":[436,457],"Honoraria:":[437,629],"Kite/Gilead;":[438,456],"BMS;":[439],"Novartis;":[440],"Amgen;":[441,478,538],"Pfizer;":[442],"Beigene;":[443],"Adaptive;":[444],"Century":[445],"Therapeutics;":[446,703],"Autolus":[447],"Kite;":[450],"Servier;":[451],"Jazz":[452],"Pharma":[453],"Chair,":[460],"NCCN":[461],"Adult":[462],"ALL":[463],"subcommittee":[464],"J.":[465,499,556],"Wu":[466],"Employment":[467,486,545,558,571],"leadership":[469,488,547,560,573],"position:":[470,489,548,561,574],"company":[474,493,552,565,578],"Stock":[475,494,553,566,579],"ownership:":[476,495,554,567,580],"Gilead;":[477],"Abbott;":[479],"AbbVie;":[480,589,630],"Avid;":[481],"Curis;":[482],"Viracta":[483],"T.":[484],"Itani":[485],"Sciences":[497,582],"Zoratti":[500],"RainCity":[503,518],"Analytics":[504,519],"funds":[507,522],"for-profit":[509,524],"healthcare":[510,525],"companies":[511,526],"S.":[514,529],"Kanters":[515],"W.":[530,543],"Wade":[531],"Kite":[536,611,653,704],"Pharma;":[537,591,612,632,654,693,705],"Allergan/Abbvie;":[539],"Johnson":[540,542],"&":[541,614,656],"Peng":[544],"Castaigne":[557],"I.":[569],"Kloos":[570],"Wang":[584],"Acerta":[590,631,692],"ADC":[592],"Therapeutics":[593,596],"America;":[594],"Amphista":[595],"Limited;":[597,607],"AstraZeneca;":[598,633,694],"Be":[599],"Biopharma;":[600],"BeiGene;":[601,636,695],"BioInvent;":[602,637,696],"Deciphera;":[603],"DTRM":[604],"Biopharma":[605],"(Cayman)":[606],"Genentech;":[608,699],"InnoCare;":[609],"Janssen;":[610,652,701],"Leukemia":[613,655],"Lymphoma":[615,657],"Society;":[616,658],"Lilly;":[617,706],"Merck;":[618,669],"Miltenyi":[619],"Biomedicine;":[620],"Milken":[621],"Institute;":[622],"Oncternal;":[623,711],"Parexel;":[624],"Pharmacyclics;":[627,678,712],"VelosBio":[628],"Bantam":[634],"Pharmaceutical;":[635],"Bristol":[638],"Myers":[639],"Squibb;":[640],"CAHON;":[641],"Dava":[642],"Oncology;":[643,708],"Eastern":[644],"Virginia":[645],"Medical":[646],"School;":[647],"Genmab;":[648,698],"i3Health;":[649],"IDEOlogy":[650],"Health;":[651],"Medscape;":[659],"Meeting":[660],"Minds":[661],"Experts;":[662],"MD":[663],"Education":[664,680],";":[665],"MJH":[666],"Life":[667],"Sciences;":[668],"Moffit":[670],"Cancer":[671],"Center;":[672],"Nurix;":[673],"Oncology":[674],"Specialty":[675],"Group;":[676],"OncLive;":[677],"Physicians":[679],"Resources":[681],"(PER);":[682],"Practice":[683],"Point":[684],"Communications":[685],"(PPC);":[686],"Studio":[687],"ER":[688],"Congressi":[689],"Celgene;":[697],"Innocare;":[700],"Juno":[702],"Loxo":[707],"Molecular":[709],"Templates;":[710],"VelosBio;":[713],"Vincerx":[714]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4379980239","counts_by_year":[],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2023-06-10T00:00:00"}
